Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor.

Abstract

To evaluate the effects of the aldose reductase inhibitor Ponalrestat (Statil) on diabetic autonomic neuropathy, a double-blind placebo controlled trial was carried out on a group of 34 diabetic patients with documented cardiac autonomic neuropathy. After a 4-week, placebo run-in period, patients were randomised for treatment with 600 mg Statil or placebo for another 24 weeks. Moreover, the reliability of the autonomic nerve function tests was investigated by comparing the results at onset and at week 4. Fifteen patients treated with Statil and 12 with placebo completed the study. Neither symptom scores nor cardiovascular reflexes, pupil reflexes and skin vasomotor reflexes improved after Statil therapy, which led us to conclude that Statil is not effective in the treatment of diabetic autonomic neuropathy. Reliability coefficients for cardiovascular reflexes and pupil reflex showed high values, ranging from 60% to 80%. Therefore these methods are recommended in future therapy trials.

• Authors: T J Faes, G A Yff, O DeWeerdt, P Lanting, J J Heimans, F W Bertelsmann
• Journal: Journal of neurology (J Neurol) Vol. 240 Issue 3 Pg. 156-60 ( 1993) ISSN: 0340-5354 [Print] Germany
• PMID: 8482988 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Phthalazines
• ponalrestat
• Aldehyde Reductase

Topics

• Aldehyde Reductase (antagonists & inhibitors)
• Autonomic Nervous System Diseases (drug therapy)
• Diabetic Neuropathies (drug therapy)
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Phthalazines (therapeutic use)
• Reproducibility of Results